|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0002475,
umls-concept:C0004587,
umls-concept:C0008976,
umls-concept:C0027651,
umls-concept:C0034656,
umls-concept:C0034897,
umls-concept:C0392756,
umls-concept:C0442124,
umls-concept:C0920317,
umls-concept:C1282910,
umls-concept:C1336527
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2004-5-7
|
|
pubmed:abstractText |
To assess, in a systematic review and meta-analysis, the relative effectiveness of intravesical mitomycin C and bacillus Calmette-Guérin (BCG) for tumour recurrence, disease progression and overall survival in patients with medium- to high-risk Ta and T1 bladder cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1464-4096
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
93
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
485-90
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15008714-Adjuvants, Immunologic,
pubmed-meshheading:15008714-Administration, Intravesical,
pubmed-meshheading:15008714-Antibiotics, Antineoplastic,
pubmed-meshheading:15008714-BCG Vaccine,
pubmed-meshheading:15008714-Humans,
pubmed-meshheading:15008714-Mitomycin,
pubmed-meshheading:15008714-Neoplasm Recurrence, Local,
pubmed-meshheading:15008714-Randomized Controlled Trials as Topic,
pubmed-meshheading:15008714-Risk Factors,
pubmed-meshheading:15008714-Urinary Bladder Neoplasms
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials.
|
|
pubmed:affiliation |
Cochrane Prostatic Diseases and Urologic Cancers Group, Velindre NHS Trust, Cardiff, UK. mike.shelley@velindre-tr.wales.nhs.uk
|
|
pubmed:publicationType |
Journal Article,
Review,
Meta-Analysis
|
